Biogen receives Investment Bank Analyst Rating Update
- ByInvesting.com-
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biogen Inc (BIIB)
218.03
-1.61(-0.73%)
- Volume:154,276
- Day's Range:216.61 - 219.45
- 52 wk Range:187.16 - 351.86
BIIB Overview
- Prev. Close
- 219.64
- Day's Range
- 216.61-219.45
- Revenue
- 10.82B
- Open
- 218.81
- 52 wk Range
- 187.16-351.86
- EPS
- 14.01
- Volume
- 154,276
- Market Cap
- 31.5B
- Dividend (Yield)
- N/A(N/A)
- Average Volume (3m)
- 989,923
- P/E Ratio
- 15.10
- Beta
- 0.387
- 1-Year Change
- -36.06%
- Shares Outstanding
- 145,113,047
- Next Earnings Date
- 24 Oct 2022
What is your sentiment on Biogen?
or
Vote to see community's results!
Biogen Inc News
- Thursday’s Top Analyst Upgrades and Downgrades: Alphabet, Autodesk, Biogen, Chipotle Mexican Grill, McDonald’s, PulteGroup, Schlumberger, Stryker, Veeva Systems and More
- By247wallst-
The futures are trading lower Thursday after the first look at second-quarter gross domestic product came in at -0.9%, spoiling the massive risk-on party that was held yesterday....
- U.S. FDA accepts Biogen’s ALS therapy for review
- ByFXEmpire-
(Reuters) -Biogen Inc’s treatment for a rare type of amyotrophic lateral sclerosis (ALS) was accepted for review by the U.S. health regulator, weeks after follow-up analyses of...
Biogen Inc Analysis
- Biogen Stock: Clinical Wins Support a Bullish Thesis
- ByTipRanks-
I am bullish on Biogen (BIIB) stock. The company's clinical momentum is heating up this summer, with one win after another. Plus, Biogen's earnings growth is indisputable. Biogen...
- FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
- ByTipRanks-
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads to the loss of everyday functions and is uniformly fatalIf...
- Biogen Inc. Q2 Earnings And Revenues Surpass Estimates
- ByTalkmarkets-
Biogen Inc. came out with quarterly earnings of $5.25 per share.
Biogen Inc Company Profile
Biogen Inc Company Profile
Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Sell | Neutral | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Buy | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,038.00 | 2,084.00 | 2,024.00 | -32.0 | -1.55% | 1.01M | London | |||
| 128.60 | 134.00 | 127.00 | -5.40 | -4.03% | 2.22M | London | |||
| 223.00 | 230.00 | 208.10 | +3.00 | +1.36% | 193.40K | London | |||
| 1,832.50 | 1,835.50 | 1,818.50 | +2.00 | +0.11% | 2.49M | London | |||
| 8.24 | 14.00 | 7.77 | -12.56 | -60.38% | 221.46M | London | |||
| 147.40 | 151.20 | 147.40 | -3.40 | -2.25% | 2.39M | London | |||
| 62.50 | 62.50 | 62.50 | +1.10 | +1.79% | 268.81K | London | |||
| 166.00 | 174.20 | 166.00 | -6.50 | -3.77% | 7.41M | London | |||
| 32.80 | 33.00 | 31.20 | +1.85 | +5.98% | 481.33K | London | |||
| 2,966.50 | 3,030.00 | 2,911.50 | -36.0 | -1.20% | 2.41M | London | |||
| 49.76 | 50.65 | 48.80 | -0.89 | -1.76% | 4.48M | London | |||
| 2,422.00 | 2,621.00 | 2,422.00 | -176.0 | -6.77% | 586.19K | London | |||
| 486.70 | 490.45 | 481.85 | +3.80 | +0.79% | 24.05M | London | |||
| 42.00 | 42.00 | 42.00 | 0.00 | 0.00% | 191.77K | London | |||
| 210.00 | 213.00 | 208.00 | -6.00 | -2.80% | 172.88K | London |
- 07 Jun 2021, 16:32Hit the jackpot with this one kaching
- 01 Feb 2021, 14:49Biib is going to give eps $30.21/share,is good buy for long term.
- 30 Jan 2021, 00:17Strong buy, biib upgrade target price to $385..stock will up again on next Monday.
- 26 Jan 2021, 15:53Eps 30.21/share, is a good buy..
- 25 Jan 2021, 03:03Biib is very good stock, can invest for long term. Share will up soon, eps will given on Feb 03,means you need to hold the stock on around Feb 1st
- 06 Feb 2020, 18:02bull...call
- 30 Jan 2020, 20:08Why has the stock gone down???
- 03 Apr 2019, 13:36where do u see biib on the short run ??!!